Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL584478

CNc1ccccc1.O=C(O)C(F)(F)F

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.61
PDK1 Q15118 2/20 0.47
PDK2 Q15119 2/20 0.47
PDK3 Q15120 2/20 0.47
PDK4 Q16654 2/20 0.47
CHIT1 Q13231 1/20 0.47
CES1 P23141 2/20 0.45
NAPRT Q6XQN6 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TP53 P04637 1/20 0.43
EPHX1 P07099 1/20 0.43
EPHX2 P34913 1/20 0.43
CDK9 P50750 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
HDAC3 O15379 2/20 0.42
HDAC4 P56524 2/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC7 Q8WUI4 2/20 0.42
HDAC2 Q92769 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL9333894 1.00 TSHR (0.61) TSHRPDK1PDK2PDK3PDK4
Trifluoroacetic Acid SCHEMBL3556372 0.89 TSHR (0.48) TSHRPDK1PDK2PDK3PDK4
Trifluoroacetic Acid SCHEMBL29059043 0.83 NPC1 (0.44) TSHRCHIT1HSD17B10TP53SMN1; SMN2
Trifluoroacetic Acid SCHEMBL584210 0.83 MAPT (0.49) CES1SMN1; SMN2HDAC1HDAC7HDAC8
Trifluoroacetic Acid SCHEMBL27939406 0.83 ALOX5 (0.48) TSHRPDK1PDK2PDK3PDK4
Trichloroacetic Acid SCHEMBL3973964 0.83 TSHR (0.61) TSHRPDK1PDK2PDK3PDK4
Trifluoroacetic Acid SCHEMBL11500234 0.82 CHIT1 (0.42) TSHRPDK1PDK2PDK3PDK4
Diphenylamine SCHEMBL31175857 0.82 HSD17B10 (0.57) TSHRCES1HSD17B10SMN1; SMN2L3MBTL1
Trifluoroacetic Acid SCHEMBL21177989 0.82 EPHX2 (0.46) TSHRTP53EPHX2SMN1; SMN2KIF11
Trifluoroacetic Acid SCHEMBL28860217 0.82 TRPV1 (0.47) TSHRHSD17B10TP53HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114644602-B Preparation method of dihydro isoxazole compound 帕潘纳(北京)科技有限公司 2024-09-03 CN claimed
US-20200131431-A1 CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS ALCHEMY SCIENCES INC (US) 2020-04-30 US claimed
US-7709169-B2 Charge trapping releaser containing charge transport layer photoconductors XEROX CORPORATION (US) 2010-05-04 US claimed
US-7687212-B2 Charge trapping releaser containing photogenerating layer photoconductors XEROX CORPORATION (US) 2010-03-30 US claimed
US-20090092909-A1 CHARGE TRAPPING RELEASER CONTAINING PHOTOGENERATING LAYER PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-04-09 US claimed
US-20090092908-A1 CHARGE TRAPPING RELEASER CONTAINING CHARGE TRANSPORT LAYER PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-04-09 US claimed
US-7235660-B1 Facile process for the preparation of high-purity aminopterin NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-06-26 US claimed
US-6372030-B1 INK VEHICLE SELECTED FROM 4-(HEXADECYLAMINO)BENZYLAMINE, N-OCTANOYL-N-METHYL GLUCAMINE, OCTANOIC HYDRAZIDE, 4-HEXADECYL SULFONYL ANILINE, A CONDUCTIVE COMPLEX OF AN AMINE COMPOUND WITH A PHOSPHORUS OR SULFUR-CONTAINING ACID XEROX CORPORATION 2002-04-16 US claimed
EP-0225823-B1 PROCESS FOR THE PREPARATION OF PTERIDINE DERIVATIVES RHONE-POULENC SANTE (FR) 1990-01-31 EP claimed
US-4767859-A Process for the preparation of pteridine derivatives RHONE-POULENC SANTE (FR) 1988-08-30 US claimed
US-12540144-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2026-02-03 US disclosed
CN-116102510-B Preparation method of 3-bromo-5, 5-dimethyl-4, 5-dihydro-isoxazole 江西仰立新材料有限公司 2025-03-25 CN disclosed
CN-113891882-B Process for producing dihydroisoxazole 组合化学工业株式会社 2024-11-26 CN disclosed
CN-114644602-B Preparation method of dihydro isoxazole compound 帕潘纳(北京)科技有限公司 2024-09-03 CN disclosed
US-20240239810-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2024-07-18 US disclosed
EP-0127143-B1 NOVEL ARYLOXYCYCLOALKANOLAMINOALKYLENE ARYL KETONES MERRELL DOW PHARMACEUTICALS INC. (US) 1990-03-21 EP disclosed
US-4868315-A HYPOTENSIVE AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1989-09-19 US disclosed
US-4767859-A Process for the preparation of pteridine derivatives RHONE-POULENC SANTE (FR) 1988-08-30 US disclosed
US-4745222-A HYPOTENSIVE AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1988-05-17 US disclosed
EP-0127143-A2 Novel aryloxycycloalkanolaminoalkylene aryl ketones MERRELL DOW PHARMACEUTICALS INC. (US) 1984-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540144-B2 Rapafucin derivative compounds and methods of use thereof RICTOR, CHP1, FKBP8 TSHR 2134/4885PDK1 4530/4885PDK2 4560/4885
US-20240239810-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, MTOR, FKBP14 TSHR 4022/4885PDK1 1870/4885PDK2 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.